Alberta Investment Management Corp Invests $5.31 Million in Edwards Lifesciences Corporation $EW

Alberta Investment Management Corp bought a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 68,300 shares of the medical research company’s stock, valued at approximately $5,312,000.

A number of other institutional investors also recently bought and sold shares of the stock. True Wealth Design LLC increased its position in Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 259 shares during the last quarter. NewSquare Capital LLC lifted its holdings in shares of Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after acquiring an additional 134 shares during the last quarter. Rakuten Securities Inc. boosted its stake in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Hantz Financial Services Inc. grew its holdings in Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares during the last quarter. Finally, Steigerwald Gordon & Koch Inc. bought a new position in Edwards Lifesciences during the 3rd quarter valued at about $30,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Up 0.7%

Shares of NYSE:EW opened at $78.97 on Thursday. The business’s 50 day moving average is $82.97 and its 200 day moving average is $81.04. The stock has a market cap of $45.82 billion, a P/E ratio of 43.15, a price-to-earnings-growth ratio of 2.08 and a beta of 0.94. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same quarter in the prior year, the company posted $0.59 earnings per share. Edwards Lifesciences’s quarterly revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Mizuho raised their price objective on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Stifel Nicolaus set a $110.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday, January 20th. Barclays reissued an “overweight” rating and set a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Truist Financial set a $89.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research report on Wednesday, February 11th. Finally, Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a research note on Monday, January 12th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $96.14.

Insider Buying and Selling

In other news, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the sale, the chief financial officer owned 39,898 shares of the company’s stock, valued at approximately $3,370,184.06. This represents a 16.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total transaction of $87,328.30. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 43,804 shares of company stock valued at $3,699,082 over the last three months. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.